Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Government Shutdown Plan Ready, Just In Case

Executive Summary

With a little more than a week left for Congress to extend government funding, US FDA and HHS plan for furloughs should no new appropriations be enacted.

You may also be interested in...



FDA Gains Budget Increase In FY 2017 … And Not Through Fees

Omnibus legislation to fund the federal government for FY 2017 includes an increase in non-user fee funds, which should please stakeholders.

US FDA Gains Budget Increase In FY 2017… And Not Through Fees

Omnibus legislation to fund the federal government for FY 2017 includes an increase in non-user fee funds, which should please stakeholders.

US FDA Gains Budget Increase In FY 2017…And Not Through Fees

Omnibus legislation to fund the federal government for the remainder of FY 2017 includes a switch from what has been a growing trend of FDA's increasing reliance on industry user fees as opposed to congressional appropriations. Non-user-fee budget authority will grow, while fee amounts dropped for the fiscal year.

Related Content

Topics

UsernamePublicRestriction

Register

PS120456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel